Vera Mastey
Regeneron (United States)(US)
Publications by Year
Research Areas
Dermatology and Skin Diseases, Asthma and respiratory diseases, Long-Term Effects of COVID-19, Health Systems, Economic Evaluations, Quality of Life, Allergic Rhinitis and Sensitization
Most-Cited Works
- → Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis(2016)1,988 cited
- → Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial(2017)1,211 cited
- → Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial(2015)564 cited
- → Peak Pruritus Numerical Rating Scale: psychometric validation and responder definition for assessing itch in moderate‐to‐severe atopic dermatitis(2019)356 cited
- → Donepezil Is Associated with Delayed Nursing Home Placement in Patients with Alzheimer's Disease(2003)313 cited
- → Patient burden of moderate to severe atopic dermatitis (AD): Insights from a phase 2b clinical trial of dupilumab in adults(2016)299 cited
- → Efficacy of Donepezil on Maintenance of Activities of Daily Living in Patients with Moderate to Severe Alzheimer's Disease and the Effect on Caregiver Burden(2003)203 cited
- → Alzheimer’s disease and related dementias increase costs of comorbidities in managed Medicare(2002)183 cited
- → Dupilumab therapy provides clinically meaningful improvement in patient-reported outcomes (PROs): A phase IIb, randomized, placebo-controlled, clinical trial in adult patients with moderate to severe atopic dermatitis (AD)(2016)161 cited
- → Association of Inadequately Controlled Disease and Disease Severity With Patient-Reported Disease Burden in Adults With Atopic Dermatitis(2018)134 cited